The second annual symposium on the future of lung cancer: a translational focus
作者： Ranee Mehra
DOI: 10.1517/14728222.10.3.475
关键词: Pharmacology 、 Cancer research 、 Mechanism (biology) 、 Treatment of lung cancer 、 Lung cancer 、 Protein kinase B 、 Histone deacetylase 、 EGFR inhibitors 、 Epidermal growth factor receptor 、 Medicine 、 Angiogenesis Pathway
摘要: Lung cancer continues to be a leading cause of death in the US, and its most advanced stages remains incurable. Cytotoxic chemotherapies have been standard care for treatment unresectable disease. However, recent advances development epidermal growth factor receptor (EGFR) inhibitors led way new generation targeted biological agents. During second annual symposium entitled ‘the future lung cancer: translational focus’, which was sponsored by Physician´s Education Resource, strategies were discussed. Besides role EGFR inhibitors, potential targets include angiogenesis pathway; other pathways, such as phosphoinositol-3 kinase/Akt Raf-MEK; 26S proteasome, histone deacetylase mechanism; TNF-related apoptosis-inducing receptors. Agents that are directed against these all varying clinical development. As more is learned about their mechanisms ...
elsevier.com
sci-hub.se 参考文章(27)
Matthew D. Beal, Gregory A. Otterson, Romola R. Lakshmanan, Wei Guo Zhu, DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors Cancer Research. ,vol. 61, pp. 1327- 1333 ,(2001)
Carol Aghajanian, Sandra Pezzulli, Martee L. Hensley, Christine S. Pien, Don S. Dizon, Paul Sabbatini, Vincent Miller, Christina Canales, Adil Daud, Peter J. Elliott, Steven Soignet, Julian Adams, David R. Spriggs, A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clinical Cancer Research. ,vol. 8, pp. 2505- 2511 ,(2002)
G. M. Strauss, J. Herndon, M. A. Maddaus, D. W. Johnstone, E. A. Johnson, D. M. Watson, D. J. Sugarbaker, R. L. Schilsky, M. R. Green, Randomized Clinical Trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB Non-Small Cell Lung Cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633 Journal of Clinical Oncology. ,vol. 22, pp. 7019- 7019 ,(2004) , 10.1200/JCO.2004.22.14_SUPPL.7019
Catherine Wheeler, Hironobu Minami, Hiromichi Ebi, Makoto Tahara, Yasutsuna Sasaki, Noboru Yamamoto, Yasuhide Yamada, Tomohide Tamura, Nagahiro Saijo, P-359 Results from a phase I study of the oral VEGF receptor tyrosine kinase inhibitor ZD6474, in patients with solid tumors Lung Cancer. ,vol. 41, ,(2003) , 10.1016/S0169-5002(03)92327-0
William Pao, Vincent A Miller, Katerina A Politi, Gregory J Riely, Romel Somwar, Maureen F Zakowski, Mark G Kris, Harold Varmus, Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain PLoS Medicine. ,vol. 2, pp. e73- ,(2005) , 10.1371/JOURNAL.PMED.0020073
S. Holden, S. Eckhardt, R. Basser, D. Rischin, H. Hurwitz, R. DeBoer, M. Rosenthal, H. Swaisland, M. McKinley, L. Schacter, Effects of ZD6474, an orally active inhibitor of VEGF receptor tyrosine kinase, in patients with solid tumors: Results from a phase I study European Journal of Cancer. ,vol. 37, ,(2001) , 10.1016/S0959-8049(01)80749-8
A. Jemal, T. Murray, E. Ward, A. Samuels, R. C. Tiwari, A. Ghafoor, E. J. Feuer, M. J. Thun, Cancer statistics, 2005. CA: A Cancer Journal for Clinicians. ,vol. 55, pp. 10- 30 ,(2005) , 10.3322/CANJCLIN.55.1.10
Joan H. Schiller, David Harrington, Chandra P. Belani, Corey Langer, Alan Sandler, James Krook, Junming Zhu, David H. Johnson, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. The New England Journal of Medicine. ,vol. 346, pp. 92- 98 ,(2002) , 10.1056/NEJMOA011954
Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A. Okimoto, Brian W. Brannigan, Patricia L. Harris, Sara M. Haserlat, Jeffrey G. Supko, Frank G. Haluska, David N. Louis, David C. Christiani, Jeff Settleman, Daniel A. Haber, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib The New England Journal of Medicine. ,vol. 350, pp. 2129- 2139 ,(2004) , 10.1056/NEJMOA040938
Fortunato Ciardiello, Gabriella Fontanini, Francesca Carlomagno, A Raffaele Bianco, Teresa Troiani, Bianca Maria Veneziani, Vincenzo Damiano, Rosa Caputo, Roberta Caputo, Giampaolo Tortora, Donatella Vitagliano, Antitumor Effects of ZD6474, a Small Molecule Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, with Additional Activity against Epidermal Growth Factor Receptor Tyrosine Kinase Clinical Cancer Research. ,vol. 9, pp. 1546- 1556 ,(2003)